GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE

CRESCENT BIOPHARMA, INC.

GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.
Transaction terms: $8M enterprise value for GLYC, $50M for Crescent, $125M concurrent PIPE.
No GlycoMimetics executives will be retained or receive equity post-closing; no financial projections made.
Term Sheet Committee formed with Mr. Junius and Mr. Pearson; dissolved after Merger Agreement execution.
Supplemental tables update precedent IPOs, public companies, M&A, and reverse merger comparisons.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.